Everolimus: a new hope for patients with breast cancer.
作者： Mehmet A.N. Sendur , Nurullah Zengin , Sercan Aksoy , Kadri Altundag
DOI: 10.1185/03007995.2013.846253
关键词:
摘要: AbstractBackground:Breast cancer cells can develop resistance to standard hormonal treatment and chemotherapy with the activation of mTOR pathway; this is supported by results preclinical clinical studies. In trials, addition everolimus or anti-HER2 improved outcomes breast patients. The aim review discuss efficacy safety data in all categories recent published studies.Scope:Everolimus showed positive A literature search was made from PubMed, ASCO San Antonio Breast Cancer Symposium Meeting abstracts using following key words: ‘everolimus’, ‘RAD001’, ‘mTOR inhibitor’, ‘breast cancer’ ‘endocrine therapy resistance’ ‘HER-2 targeted therapies’. last on June 10, 2013. most important limitation our that rely phase I II trials.Findings:Preclinical studies tha...
informahealthcare.com参考文章(80)
Ming Tan, Mien Chie Hung, Dihua Yu, Bolin Liu, Shan Shue Wang, Junzhi Li, Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. ,vol. 13, pp. 1359- 1365 ,(1996)
Howard A. Burris, Fabienne Lebrun, Hope S. Rugo, J. Thaddeus Beck, Martine Piccart, Patrick Neven, Jose Baselga, Katarina Petrakova, Gabriel N. Hortobagyi, Anna Komorowski, Edmond Chouinard, Robyn Young, Michael Gnant, Kathleen I. Pritchard, Lee Bennett, Jean-Francois Ricci, Hounayda Bauly, Tetiana Taran, Tarek Sahmoud, Shinzaburo Noguchi, Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer. ,vol. 119, pp. 1908- 1915 ,(2013) , 10.1002/CNCR.28010
Stacy Moulder, Gregory Gladish, Joe Ensor, Ana Maria Gonzalez-Angulo, Massimo Cristofanilli, James L. Murray, Daniel Booser, Sharon H. Giordano, Abeena Brewster, Julia Moore, Edgardo Rivera, Gabriel N. Hortobagyi, Hai T. Tran, A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer Cancer. ,vol. 118, pp. 2378- 2384 ,(2012) , 10.1002/CNCR.26571
Early Breast Cancer Trialists' Collaborative Group, None, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials The Lancet. ,vol. 365, pp. 1687- 1717 ,(2005) , 10.1016/S0140-6736(05)66544-0
Parvin F. Peddi, Rebecca A. Shatsky, Sara A. Hurvitz, Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer Cancer Treatment Reviews. ,vol. 40, pp. 320- 326 ,(2014) , 10.1016/J.CTRV.2013.08.004
R L Dillon, D E White, W J Muller, The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene. ,vol. 26, pp. 1338- 1345 ,(2007) , 10.1038/SJ.ONC.1210202
Winnie Yeo, Paul K.S. Chan, Sheng Zhong, Wing M. Ho, Joyce L. Steinberg, John S. Tam, Pun Hui, Nancy W.Y. Leung, Benny Zee, Philip J. Johnson, Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors Journal of Medical Virology. ,vol. 62, pp. 299- 307 ,(2000) , 10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0
Flora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, Martin Filipits, Rupert Bartsch, None, mTOR inhibitors in breast cancer: A systematic review Gynecologic Oncology. ,vol. 127, pp. 662- 672 ,(2012) , 10.1016/J.YGYNO.2012.08.040
Nadia Margariti, Stephen B. Fox, Alberto Bottini, Daniele Generali, "Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future? Breast Cancer Research and Treatment. ,vol. 128, pp. 599- 606 ,(2011) , 10.1007/S10549-010-0986-9
Antonio C. Wolff, Ann A. Lazar, Igor Bondarenko, August M. Garin, Stephen Brincat, Louis Chow, Yan Sun, Zora Neskovic-Konstantinovic, Rodrigo C. Guimaraes, Pierre Fumoleau, Arlene Chan, Soulef Hachemi, Andrew Strahs, Maria Cincotta, Anna Berkenblit, Mizue Krygowski, Lih Lisa Kang, Laurence Moore, Daniel F. Hayes, Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 31, pp. 195- 202 ,(2013) , 10.1200/JCO.2011.38.3331